Troponin I Testing Recommendations for Acute Myocardial Infarction

Timing of Serial Testing

Initial measurement at presentation (time 0) and a repeat 3–6 hours after symptom onset is recommended for all patients with suspected acute coronary syndrome (ACS). ACC/AHA guideline 1
High‑sensitivity troponin I assays allow the second sample to be drawn 1–3 hours after the initial draw. ACC guideline 3
Extended testing beyond 6 hours should be performed when the first two results are normal but the patient has electrocardiographic changes or intermediate‑to‑high‑risk clinical features. ACC/AHA guideline 2
If presentation occurs ≤3 hours after symptom onset and the first two troponins are normal, a third measurement at 12–24 hours is advised when clinical suspicion remains high. ACC/AHA guideline 4
For suspected reinfarction during hospitalization, obtain an immediate troponin I sample when symptoms recur and repeat 3–6 hours later; a ≥20 % increase confirms recurrent infarction. ACC/AHA guideline 5
Optional late measurement on day 3 or 4 can be used as an index of infarct size; this is a Class IIb recommendation. ACC/AHA guideline 1

Troponin I above the 99th percentile of the assay‑specific upper reference limit defines myocardial injury. ACC/AHA guideline 6
Acute myocardial infarction (AMI) diagnosis requires both:

When the initial troponin is already elevated, a ≥20 % change between serial measurements confirms acute injury. ACC/AHA guideline 5
When the value is near the 99th percentile, a change of ≥3 standard deviations of the assay’s analytical variation is required. ACC guideline 6
Contemporary assays have analytical variation of 5–7 % at relevant concentrations; therefore a 20 % change exceeds analytical noise and indicates true dynamic change. ACC guideline 6

The 99th‑percentile cutoff must be validated for each laboratory assay used. ACC/AHA guideline 4
The assay should demonstrate a coefficient of variation ≤10 % at the 99th‑percentile threshold. ACC/AHA guideline 4
Sex‑specific 99th‑percentile values should be applied when available to improve diagnostic accuracy. ACC guideline 6

A single elevated troponin I without a dynamic change does not confirm AMI; chronic conditions (e.g., advanced kidney disease, heart failure, tachyarrhythmias, myocarditis/pericarditis, pulmonary embolism, sepsis, severe burns, respiratory failure) can cause persistent elevation. ACC/AHA guideline 6
The rising/falling pattern differentiates acute MI from chronic background elevation. ACC/AHA guideline 5
Troponin I may remain elevated for 7–14 days after infarction; late presenters (>24 hours) may lack a clear dynamic change yet can still be diagnosed if the clinical context supports AMI. ACC/AHA guideline 4

Higher troponin I concentrations correlate with larger infarct size and predict both short‑term and long‑term mortality. ACC/AHA guideline 1
The magnitude of troponin elevation identifies high‑risk patients who benefit from intensive medical therapy and early invasive management. ACC/AHA guideline 2

Creatine kinase‑MB (CK‑MB) and myoglobin should not be used when contemporary troponin I assays are available, as they lack cardiac specificity and add no diagnostic value. ACC/AHA guideline 1